Jaffetilchin Investment Partners LLC purchased a new position in shares of Steris PLC (NYSE:STE) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 4,674 shares of the medical equipment provider’s stock, valued at approximately $409,000.
A number of other institutional investors have also modified their holdings of STE. The Manufacturers Life Insurance Company boosted its position in shares of Steris by 1.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 122,520 shares of the medical equipment provider’s stock worth $9,986,000 after purchasing an additional 1,963 shares in the last quarter. Prudential Financial Inc. lifted its position in Steris by 14.4% in the 3rd quarter. Prudential Financial Inc. now owns 192,686 shares of the medical equipment provider’s stock valued at $17,034,000 after acquiring an additional 24,220 shares in the last quarter. Canada Pension Plan Investment Board lifted its position in Steris by 13.2% in the 3rd quarter. Canada Pension Plan Investment Board now owns 54,100 shares of the medical equipment provider’s stock valued at $4,782,000 after acquiring an additional 6,300 shares in the last quarter. Keybank National Association OH bought a new position in Steris in the 3rd quarter valued at about $554,000. Finally, First Trust Advisors LP lifted its position in Steris by 84.6% in the 2nd quarter. First Trust Advisors LP now owns 15,865 shares of the medical equipment provider’s stock valued at $1,293,000 after acquiring an additional 7,272 shares in the last quarter. Hedge funds and other institutional investors own 89.44% of the company’s stock.
In other Steris news, VP John Adam Zangerle sold 3,650 shares of the business’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $88.00, for a total value of $321,200.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Michael J. Tokich sold 11,000 shares of the business’s stock in a transaction dated Monday, October 23rd. The shares were sold at an average price of $92.00, for a total transaction of $1,012,000.00. Following the transaction, the insider now owns 58,588 shares in the company, valued at approximately $5,390,096. The disclosure for this sale can be found here. Insiders own 2.55% of the company’s stock.
Steris PLC (STE) opened at $91.43 on Friday. The company has a market cap of $7,816.31, a price-to-earnings ratio of 54.42 and a beta of 1.27. The company has a current ratio of 2.80, a quick ratio of 2.18 and a debt-to-equity ratio of 0.48. Steris PLC has a 1 year low of $65.26 and a 1 year high of $93.71.
Steris (NYSE:STE) last released its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $0.94 EPS for the quarter, missing analysts’ consensus estimates of $0.95 by ($0.01). Steris had a net margin of 5.59% and a return on equity of 11.49%. The firm had revenue of $634.20 million for the quarter, compared to analysts’ expectations of $629.02 million. During the same quarter last year, the firm earned $0.89 earnings per share. The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. sell-side analysts anticipate that Steris PLC will post 4.06 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, December 20th. Stockholders of record on Wednesday, November 22nd were issued a dividend of $0.31 per share. This represents a $1.24 dividend on an annualized basis and a dividend yield of 1.36%. The ex-dividend date of this dividend was Tuesday, November 21st. Steris’s dividend payout ratio is currently 73.81%.
STE has been the topic of several recent analyst reports. Zacks Investment Research raised shares of Steris from a “hold” rating to a “buy” rating and set a $101.00 target price on the stock in a research report on Monday, October 9th. KeyCorp restated a “buy” rating and set a $91.00 price target on shares of Steris in a research note on Tuesday, October 17th. Raymond James Financial restated a “market perform” rating and set a $100.00 price target on shares of Steris in a research note on Wednesday, January 3rd. Finally, TD Securities raised their price target on shares of Steris from C$14.00 to C$16.00 and gave the stock a “buy” rating in a research note on Thursday, November 9th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $79.50.
Steris Company Profile
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.